Respiratory syncytial virus is a common, highly contagious illness that often causes mild upper respiratory symptoms, akin to a cold. In babies, particularly those with tiny airways, RSV can cause the ...
AstraZeneca 4Q Revenues: $14.9 billion (+24%) 4Q Earnings: $1.5 billion (+56%) FY Revenues: $54.1 billion (+18%) FY Earnings: ...
Almost no other industry goes as far as the phrase "defensive" as the healthcare sector, which encompasses a wide range of ...
It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...
The final obstacle to the routine use of Sanofi and AstraZeneca's Beyfortus to prevent respiratory syncytial virus (RSV) in the US has fallen after it was backed by Centres for Disease Control and ...
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...
A second study, also published today in the same journal, looked at patients seen at the Beth Israel Deaconess Medical Center in Boston and found a lower uptake of maternal RSV vaccine and nirsevimab ...
Hamilton families have one last chance to get their babies immunized against a common virus that can cause serious lung infections before a clinic at McMaster Children’s Hospital closes. The last ...
When existing systems do not accommodate access to health care innovation, we must change those systems. Fulfilling nirsevimab’s promise will require overcoming entrenched hospital payment norms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results